There are two histological types of pyogenic granuloma (PG) of the oral cavity: the lobular capillary hemangioma (LCH) and non-LCH type. The aim of the present study was to examine and compare the clinical features, etiological factors, diameter of vascular elements and immunohistochemical features of LCH and non-LCH histological types of PG to determine whether they are two distinct entities. Thirty cases of LCH and 26 cases of non-LCH PG were retrieved and retrospectively studied. Clinically, LCH PG occurred more frequently (66.4%) as sessile lesion whereas non-LCH PG occurred as pedunculated (77%). Non-LCH PG was associated more frequently (86.4%) with etiological factors. The lobular area of the LCH PG contained a greater number of blood vessels with small luminal diameter than did the central area of non-LCH PG. In the central area of non-LCH PG a significantly greater number of vessels with perivascular mesenchymal cells non-reactive for alpha-smooth muscle actin and muscle-specific actin was present than in the lobular area of LCH PG. The differences found in the present study suggest that the two histological types of PG represent distinct entities.
A basal cell maxillary ameloblastoma became obvious as an asymptomatic swelling of the left buccal sulcus and alveolar process, although a large extension into the maxillary sinus up to the nasal conchae and the orbital floor had already occurred. The painless and slow growth of the lesion, the thin bone of the upper jaws, the adjacent cavities and the vital structures are the main factors for delay in recognition and thus the potentially lethal result of a maxillary ameloblastoma. A review of location, age, sex and race predilection, clinical course, radiographic appearance, histological types and treatment methods is made.
Six cases reconstructed in the zygomatico-frontoorbital region with titanium mesh are reported and a discussion of the use of this material in oral and maxillofacial surgery is presented.
ObjectivesThe purpose of this study was to evaluate the oral health-related quality of
life of patients treated with implant-supported mandibular overdentures and to compare
the attachment systems used.Material and MethodsThe presence of myofibroblasts as well as transforming growth
factor-beta1 was examined in twenty cases of fibrous epulis and 22
ossifying fibrous epulis, using immunohistochemistry.ResultsMyofibroblasts positive for alpha smooth muscle actin and vimentin but
negative to desmin were found in 20% and 45% in fibrous epulis and
ossifying fibrous epulis, respectively. Myofibroblasts were distributed
in areas with and without inflammatory infiltration and their presence
in inflammatory areas was not related with the degree of inflammatory
infiltration. A percentage of 21 - 60% of fibroblasts and chronic
inflammatory cells expressed transforming growth factor-beta1 in all
cases.ConclusionsThese data suggest that transforming growth factor-beta1 and
myofibroblasts contribute to the formation of collagenous connective
tissue in fibrous epulis and ossifying fibrous epulis. Myofibroblasts
are mainly presented in ossifying fibrous epulis than in fibrous epulis.
It seems to be no relationship between the presence of myofibroblasts
and the degree of inflammatory infiltration of the lesions.
Our immunohistochemical findings, and especially the positive expression of vimentin from the epithelial cells of COF suggests that these cells are primordial. Last but not least, the presence of a relative small number of myofibroblasts in the stroma justifies the non-aggressive behavior of the neoplasm and supports that a part of stromal collagen of COF is produced by these cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.